• Company
• Conquest of low survival gallbladder cancer
• by Nov 14, 2023 05:49am

• Policy
• Drug pricing adjustment guidelines to be established soon
• by Lee, Tak-Sun Nov 14, 2023 05:49am

• Policy
• Regeneron enters Phase 3 in Korea
• by Lee, Hye-Kyung Nov 13, 2023 05:23am

• Company
• Novartis loses 2nd trial for its Entresto patent
• by Kim, Jin-Gu Nov 13, 2023 05:23am

• Company
• Amvuttra receives orphan drug designation
• by Eo, Yun-Ho Nov 13, 2023 05:23am

• Policy
• Looking at the review date for GIFT No. 1 Lunsumio
• by Lee, Hye-Kyung Nov 13, 2023 05:23am

• Company
• NMOSD drug Enspryng likely to be reimbursed in December
• by Eo, Yun-Ho Nov 13, 2023 05:23am

• Opinion
• [Reporter’s view] Successive large-scale technology exports
• by Kim, Jin-Gu Nov 10, 2023 05:19am

• Product
• ‘Cutting budget for essential drugs neglects public health'
• by Kang, Hye-Kyung Nov 10, 2023 05:19am

• Company
• Korea Pharma applies for approval of its 24hr ADHD drug
• by Lee, Seok-Jun Nov 10, 2023 05:19am